Abstract:Glioblastoma (GBM) is highly invasive and the deadliest brain tumor in adults. It is characterized by inter-tumor and intra-tumor heterogeneity, short patient survival, and lack of effective treatment. Prognosis and therapy selection is driven by molecular data from gene transcription, genetic alterations and DNA methylation. The four GBM molecular subtypes are proneural, neural, classical, and mesenchymal. More effective personalized therapy heavily depends on higher resolution molecular subtype signatures, combined with gene therapy, immunotherapy and organoid technology. In this review, we summarize the principal GBM molecular classifications that guide diagnosis, prognosis, and therapeutic recommendations.

What problem does this paper attempt to address?

The problem this paper attempts to address is the high heterogeneity of glioblastoma (GBM) and the challenges in clinical diagnosis, prognosis, and treatment options. GBM is the most aggressive and deadly brain tumor in adults, characterized by significant inter-tumor and intra-tumor heterogeneity, short patient survival, and a lack of effective treatments. Currently, it is becoming increasingly important to guide clinical diagnosis, prognosis, and treatment options through molecular data such as gene transcription, genetic variation, and DNA methylation. Specifically, this paper aims to: 1. **Summarize current research on the molecular characteristics of GBM**: including classification methods based on transcription levels, genetic variation, and DNA methylation. 2. **Describe the relationships between different classification methods**: exploring how these classification methods complement each other to improve the accuracy of diagnosis and treatment. 3. **Provide diagnostic and therapeutic guidance strategies based on molecular characteristics**: emphasizing the importance of high-resolution molecular subtype characteristics in personalized treatment, combined with the application of gene therapy, immunotherapy, and organoid technology. Through these studies, the paper hopes to provide more precise and personalized guidance for the clinical management and treatment of GBM, thereby improving patient prognosis and survival rates.

Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy